Congress-HFA
Congress-HFA

Transthyretin Amyloidosis (ATTR)

Heart Failure Association (HFA) 2025

Congress Details

calanderMay 17-20, 2025

locationBelgrade, Serbia

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Oral

Congress Materials

Witteles_HFA2025_HELIOS-B+Mortality_oral_FD_DV-001350_FINAL
icon Presentation Type
Presentation
location icon Location
Belgrade, Serbia
icon Title
Vutrisiran reduces all-cause mortality, cardiovascular mortality, and cardiovascular events in patients with transthyretin amyloid cardiomyopathy: Analysis from the HELIOS-B trial
Morbach_HFA-2025-ATTR-CM-treatment-landscape-poster_FINAL_DV-001261_14Apr2025
icon Presentation Type
Poster
location icon Location
Belgrade, Serbia
icon Title
Clinical Presentation and Treatment Landscape of Patients with Transthyretin Amyloidosis With Cardiomyopathy: A Real-world Study in Five European Countries and Japan
Singh_GeneAct-poster_HFA-2025_DV-001264_10Apr2025FINAL
icon Presentation Type
Poster
location icon Location
Belgrade, Serbia
icon Title
Utility of Genetic Testing For Diagnosing hATTR Patients: Results from a European and Middle East Genetic Testing Programme
Fontana_HFA-2025-Nucre-Phase-3-trial-design-poster_FINAL-watermarked_DV-001263_14Apr25FINAL
icon Presentation Type
Poster
location icon Location
Belgrade, Serbia
icon Title
TRITON-CM: A Phase 3 Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
HFA-2025_H-B-taf-progression_Rapid-Fire_17Apr25_FINAL
icon Presentation Type
Presentation
location icon Location
Belgrade, Serbia
icon Title
Vutrisiran In Patients With Transthyretin Amyloidosis with Cardiomyopathy In HELIOS-B Who Had Progressed On Tafamidis

Related Materials

Transthyretin Amyloidosis (ATTR)

Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial

European Journal of Heart Failure

Author(s)

Josephine Mansell, Xiaowen Wang, Karola S Jering, et al

June 2026

Worcester-MA-Mobile

Transthyretin Amyloidosis (ATTR)

RNA Therapeutics Symposium (RNATx) 2026

June 24-26, 2026 USA

View Details

Transthyretin Amyloidosis (ATTR)

Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension

Amyloid

Author(s)

Cécile Cauquil, David Adams, Julian Gillmore, et al

June 2026

Maastricht-NL-MOBILE

Transthyretin Amyloidosis (ATTR)

Peripheral Nerve Society (PNS) 2026

June 13-16, 2026 Netherlands

View Details

Transthyretin Amyloidosis (ATTR)

Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis

Clinical Pharmacokinetics

Author(s)

Marianna Fontana, Vincent Algalarrondo, Pablo Garcia-Pavia, et al

May 2026

Transthyretin Amyloidosis (ATTR)

Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B

JACC: Asia

Author(s)

Jin Endo, Tetsuo Minamino, Jaewon Oh, et al

May 2026